Here, we used LCMV-based, propagation-attenuated recombinant LCMV vectors with an artificial genome organization (artLCMV)31 expressing the murine melanocyte differentiation antigen TRP2 (artLCMV-TRP2) to treat orthotopically growing B16F10 melanomas (Fig. 1a). This evidence concerns the gene DCT and melanoma.